- Home
- CRVO vs KYNB Comparison
CRVO vs KYNB Comparison
Compare CRVO & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVO | KYNB |
|---|---|---|
| Founded | 2001 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 31.9M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRVO | KYNB |
|---|---|---|
| Price | $3.75 | $7.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 32.3K | 8.1K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,006,510.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.51 | $6.32 |
| 52 Week High | $13.13 | $9.58 |
Technical Indicators
Market Signals| Indicator | CRVO | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 48.94 |
| Support Level | $3.55 | $7.04 |
| Resistance Level | $4.33 | $7.50 |
| Average True Range (ATR) | 0.24 | 0.20 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 21.88 | 30.23 |
Price Performance
Historical ComparisonAbout CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.